Insmed Inc. has divulged cathepsin C (dipeptidyl peptidase I, DPP1) inhibitors reported to be useful for the treatment of amyotrophic lateral sclerosis, asthma, metastatic cancer, chronic rhinosinusitis, heart failure, inflammatory bowel disease, psoriasis and thrombosis, among others.
Shanghai Pharmaceuticals Holding Co. Ltd. has identified C-C chemokine receptor type 4 (CCR4) antagonists reported to be useful for the treatment of asthma, allergic rhinitis, atopic dermatitis, cancer, systemic lupus erythematosus, rheumatoid arthritis and drug-induced rash.
Researchers at Provincial Health Services Authority and University of British Columbia have synthesized radiolabeled peptides targeting gastrin-releasing peptide receptor (GRPR) reported to be useful for the diagnosis and treatment of cancer.
Samjin Pharmaceutical Co. Ltd. has disclosed stimulator of interferon genes protein (STING; TMEM173) agonists reported to be useful for the treatment of cancer, allergy, autoimmune diseases and inflammatory disorders.
A new study published in Nature Cancer reveals a novel regulatory mechanism of ferroptosis resistance that may help overcome therapeutic barriers in cancer treatment.
Xellsmart Biopharmaceutical (Suzhou) Co. Ltd. has announced IND clearances by the FDA for its XS-411 and XS-228 cell therapies, for Parkinson’s disease and amyotrophic lateral sclerosis (ALS), respectively.
Hansoh Pharmaceutical Group Co. Ltd. has obtained clinical trial clearance from China’s National Medical Products Administration (NMPA) for HS-10529 tablets.
Elix Inc. has entered into a drug discovery collaboration with Prism Biolab Co. Ltd. to accelerate AI-driven drug discovery for challenging protein-protein interaction targets. The partnership will combine Elix’s AI drug discovery platform with Prism’s proprietary small-molecule peptide mimetic Pepmetics technology for controlling protein-protein interactions.
At the recent European Society of Clinical Microbiology and Infectious Diseases (ESCMID) meeting in Vienna, Longhorn Vaccines & Diagnostics LLC presented data on the neutralizing antibody responses of LHNVD-202, an unconjugated composite peptide vaccine.
Researchers from Eli Lilly & Co. reported preclinical data on LY-3954068, a MAPT small-interference RNA (siRNA) strategy in AD models. The therapy is designed to reduce tau protein synthesis by inhibiting the translation of MAPT mRNA, with the goal of effectively lowering all forms of tau.
RSS
